查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1540996

2024-2032 年按療法、藥物類型、最終用戶、配銷通路和地區分類的多發性骨髓瘤藥物市場報告

Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球多發性骨髓瘤藥物市場規模達223億美元。

多發性骨髓瘤或卡勒氏症是指一種主要影響漿細胞的血癌。一些最常見的多發性骨髓瘤藥物類型包括化療藥物、皮質類固醇和免疫調節藥物。這些藥物有助於促進骨癒合，預防高血鈣、骨折、脊髓受壓和貧血，同時最大限度地減少化療的需要。化療劑包括各種蒽環類抗生素和烷化劑，例如美法崙、阿黴素、長春新鹼和脂質體阿黴素。標靶治療藥物包括蛋白酶體抑制劑，如硼替佐米，以及各種其他化合物，包括地塞米松、潑尼松和沙利度胺。

醫療保健領域的重大發展以及血液癌症盛行率的增加是推動市場成長的關鍵因素之一。多發性骨髓瘤通常是由特定的基因異常引起的，這種疾病的治療涉及調節免疫系統的藥物，並有助於提高化療、放療、幹細胞移植和血小板輸注的效率。此外，消費者對生物治療藥物益處的認知不斷提高，生物治療藥物利用人體的免疫系統來識別和攻擊骨髓瘤細胞，也推動了市場的成長。此外，各種技術進步，例如用於治療多發性骨髓瘤的 microRNA 療法和奈米藥物的開發，正在成為另一個生長誘導因素。這些藥物用於促進大分子藥物輸送到骨髓並催化抗腫瘤反應。其他因素，包括醫療保健支出的增加以及醫學領域廣泛的研發（R&D）活動，預計將進一步推動市場發展。

本報告回答的關鍵問題：

  • 迄今為止，全球多發性骨髓瘤藥物市場表現如何，未來幾年將如何表現？
  • 主要區域市場有哪些？
  • COVID-19 對全球多發性骨髓瘤藥物市場有何影響？
  • 基於該療法的市場區隔是什麼？
  • 根據藥物類型分類的市場是怎麼樣的？
  • 基於最終用戶的市場區隔是什麼？
  • 基於配銷通路的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球多發性骨髓瘤藥物市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：管道評估/臨床試驗產品/臨床開發

  • PegIntron（聚乙二醇化干擾素 alfa-2b）
  • 泊馬度胺
  • 坦斯匹黴素 (KOS-953)
  • MLN 9708
  • SRT-501-012
  • BHQ880
  • 帕比司他
  • ZIO-101
  • VEGF-Trap（阿柏西普）
  • 狄諾塞麥
  • 哌立福辛
  • Actimid (CC-5013)
  • 羅米地辛
  • 普利地辛（Aplidin）
  • 坦西羅莫司（Torisel）
  • 索拉非尼
  • 貝伐珠單抗

第 6 章：全球多發性骨髓瘤藥物市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 7 章：市場區隔：透過治療

  • 標靶治療
    • 市場趨勢
    • 市場預測
  • 生物療法
    • 市場趨勢
    • 市場預測
  • 化療
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依藥物類型

  • 免疫調節藥物
    • 市場趨勢
    • 市場預測
  • 蛋白酶體抑制劑
    • 市場趨勢
    • 市場預測
  • 組蛋白去乙醯化酶抑制劑
    • 市場趨勢
    • 市場預測
  • 單株抗體藥物
    • 市場趨勢
    • 市場預測
  • 類固醇
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 男士
    • 市場趨勢
    • 市場預測
  • 女性
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 零售藥局
    • 市場趨勢
    • 市場預測
  • 網路藥局
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 11 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 12 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 13 章：價值鏈分析

第 14 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 15 章：價格指標

第16章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • Bristol Myers Squibb
    • Daiichi Sankyo Co.
    • Sanofi-Aventis Groupe (Genzyme Corporation)
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis International AG
    • Pfizer Inc.
    • PHARMA MAR, SA
    • Takeda Pharmaceutical Company Limited.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A2169

The global multiple myeloma drugs market size reached US$ 22.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.

Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.

Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple myeloma drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapy, drug type, end-user and distribution channel.

Breakup by Therapy:

Targeted Therapy

Biologic Therapy

Chemotherapy

Others

Breakup by Drug Type:

Immunomodulatory Drugs

Proteasome Inhibitors

Histone Deacetylase Inhibitors

Monoclonal Antibody Drugs

Steroids

Others

Breakup by End-User:

Men

Women

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.

Key Questions Answered in This Report:

  • How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global multiple myeloma drugs market?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the end-user?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple myeloma drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Pipeline Assesment/Clinical Trial Products/Clinical Developments

  • 5.1 PegIntron (Pegylated interferon alfa-2b)
  • 5.2 Pomalidomide
  • 5.3 Tanespimycin (KOS-953)
  • 5.4 MLN 9708
  • 5.5 SRT-501- 012
  • 5.6 BHQ880
  • 5.7 Panobinostat
  • 5.8 ZIO-101
  • 5.9 VEGF-Trap(Aflibercept)
  • 5.10 Denosumab
  • 5.11 Perifosine
  • 5.12 Actimid (CC-5013)
  • 5.13 Romidepsin
  • 5.14 Plitidepsin (Aplidin)
  • 5.15 Temsirolimus (Torisel)
  • 5.16 Sorafenib
  • 5.17 Bevacizumab

6 Global Multiple Myeloma Drugs Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Targeted Therapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologic Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chemotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Immunomodulatory Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteasome Inhibitors
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Histone Deacetylase Inhibitors
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Monoclonal Antibody Drugs
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Steroids
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Men
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Women
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Amgen Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bristol Myers Squibb
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Daiichi Sankyo Co.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 SWOT Analysis
    • 16.3.5 Johnson & Johnson Services, Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck & Co., Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Novartis International AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Pfizer Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 PHARMA MAR, S.A.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
    • 16.3.10 Takeda Pharmaceutical Company Limited.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Teva Pharmaceutical Industries Ltd.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2023
  • Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2023
  • Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2023
  • Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
  • Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
  • Figure 92: Global: Multiple Myeloma Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2024-2032
  • Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Multiple Myeloma Drugs Market Structure
  • Table 8: Global: Multiple Myeloma Drugs Market: Key Players